ALMS Alumis Inc Future Profit

Corporate company logo of Alumis (ALMS)

Alumis Inc. (ALMS) is currently in an investment stage without its own cash flows, relying instead on shareholder equity. On GURU.Markets, the expected net profit indicator demonstrates a development vector where 0.00 becomes the new value of the metric. Alumis Inc. is developing highly selective drugs to combat neuroinflammation, focusing its R&D on innovative TYK2 inhibitors for the precision therapy of immune pathologies.

Alumis Pharma (ALMS): Net Profit Forecast from 06/29/2024 to 06/29/2024

Analytical breakdowns and data insights for company Alumis Pharma (ALMS)

- share price and consensus valuation forecast:
Stock Price alumis.com|ALMS - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Alumis Corp|ALMS - Value Adjusted for Debt and Cash
- book capitalization information:
Net Assets per Single Share Alumis|ALMS - Accounting Capitalization|Market Capitalization to Book Value Ratio alumis.com|ALMS - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Alumis Inc.|ALMS - Long-Term Debt to Capital|Short-Term Debt to Equity Alumis Inc.|ALMS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Alumis|ALMS - Long-Term Debt|Company Short-Term Debt Alumis|Quick Liquidity alumis.com
- net income and valuation ratios data:
ALMS - Company Net Income|Projected Future Earnings Alumis Inc.|ALMS - Market Cap to Net Income Ratio|Projected Price to Earnings alumis.com|ALMS - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Alumis Inc.|ALMS - Operating profit EBITDA|Earnings per share for the last twelve months Alumis|ALMS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months alumis.com|ALMS - Earnings growth in current year|Net earnings per share growth forecast for next year Alumis Inc.
- issuer revenue and sales details:
ALMS - Company Sales|Projected Sales Volume Alumis Inc|ALMS - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Alumis Pharma|ALMS - Annual Revenue Growth (Last Twelve Months)
Fundamental company valuation:ALMS, Alumis Pharma
Brand item of Alumis Corp

The assessment of the fundamental stability of Alumis Inc. (ALMS) relies on the market consensus regarding future cash flows from the implementation of innovative oral TYK2 inhibitors. The price action regarding the company's target profit level reflects aggregate analyst expectations for the monetization of clinical successes, where the upward trend confirms the business's capitalization potential, while local peaks signal a risk of asset overvaluation.

Competitors of Alumis Inc.

JAZZ (jazzpharma.com) - Projected Future Earnings|Projected Future Earnings Cytokinetics Inc|Future Profit PTCT (PTC Therapeutics Corp)|SRRK (Scholar Rock Inc.) - Expected Net Income|Expected Profit Centessa CNTA|Dyne Therapeutics (DYN) - Expected Net Profit|Edgewise Corp - Projected Future Earnings|Expected Net Profit Rapport Pharma|ZVRA (Zevra Therapeutics Inc) - Future Profit|Contineum Corp (CTNM) - Projected Future Earnings|Expected Profit Larimar Therapeutics|CAPR: Expected Net Income|Expected Profit Entrada Therapeutics, Inc (TRDA)|PTHS - Expected Net Profit|Expected Profit MediciNova Corp MNOV|Serina (SER) - Expected Net Profit|BTAI - Expected Profit|Projected Net Profit ProMIS Neurosciences Inc. (PMN)|APUS: Projected Future Earnings|Projected Net Profit AEON Biopharma AEON|Future Profit NLSP|Expected Net Profit Bionomics Limited BNOX|Projected Future Earnings HUGE|RETA (Reata Pharmaceuticals) - Expected Net Income